Mitsubishi UFJ Asset Management’s Taysha Gene Therapies TSHA Stock Holding History

Mitsubishi UFJ Asset Management’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$294K	Sell	43,191 -13,386	-24%	-$79.2K	﹤0.01%	964
2026 Q1	$253K	Sell	56,577 -1,398	-2%	-$6.5K	﹤0.01%	943
2025 Q4	$304K	Sell	57,975 -22,757	-28%	-$111K	﹤0.01%	946
2025 Q3	$264K	Buy	80,732 +161	+0.2%	+$456	﹤0.01%	964
2025 Q2	$186K	Buy	+80,571	New	+$175K	﹤0.01%	984
2022 Q2	–	Sell	-21,834	Closed	-$142K	–	1203
2022 Q1	$142K	Hold	21,834	–	–	﹤0.01%	1105
2021 Q4	$259K	Buy	+21,834	New	+$329K	﹤0.01%	1038

Other funds holding TSHA

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Mitsubishi UFJ Asset Management's TSHA Position: Q2 2026 in Review

Mitsubishi UFJ Asset Management reduced its Taysha Gene Therapies (TSHA) stake by 24% in Q2 2026, selling an estimated $79.2K and leaving 43,191 shares worth $294K. The position accounts for ﹤0.01% of the portfolio, ranked #964.

Mitsubishi UFJ Asset Management first reported a position in TSHA in Q4 2021 and has held it in 7 quarters since. The position peaked at $304K in Q4 2025. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

Mitsubishi UFJ Asset Management held 43,191 shares of Taysha Gene Therapies worth $294K as of Q2 2026.
Mitsubishi UFJ Asset Management sold 13,386 Taysha Gene Therapies shares in Q2 2026, an estimated $79.2K.
Taysha Gene Therapies made up ﹤0.01% of Mitsubishi UFJ Asset Management's portfolio in Q2 2026, its #964 holding.
Mitsubishi UFJ Asset Management first reported a position in Taysha Gene Therapies in Q4 2021 and has held it in 7 quarters since.
Mitsubishi UFJ Asset Management's Taysha Gene Therapies position peaked at $304K in Q4 2025.
209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Mitsubishi UFJ Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.